Contineum falls after missing main goals in multiple sclerosis trial [Seeking Alpha]
Contineum Therapeutics, Inc. - Common stock (CTNM)
Company Research
Source: Seeking Alpha
The trial did not achieve its main goals for effectiveness. There was no notable improvement in patients' binocular 2.5% low contrast letter acuity across the different treatment groups, the company reported. As a result, the stock has dropped approximately 8% premarket However, the trial did show that both doses were safe and well-tolerated by participants. More on Contineum Therapeutics Seeking Alpha's Quant Rating on Contineum Therapeutics Historical earnings data for Contineum Therapeutics Financial information for Contineum Therapeutics More Trending News
Show less
Read more
Impact Snapshot
Event Time:
CTNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTNM alerts
High impacting Contineum Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CTNM
News
- Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare ConferenceBusiness Wire
- Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Robert W. Baird from $16.00 to $14.00. They now have an "outperform" rating on the stock.MarketBeat
- Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Royal Bank Of Canada from $25.00 to $22.00. They now have an "outperform" rating on the stock.MarketBeat
- Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) [Yahoo! Finance]Yahoo! Finance
- Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)Business Wire
CTNM
Earnings
- 5/14/25 - Miss
CTNM
Sec Filings
- 11/20/25 - Form 8-K
- 11/4/25 - Form SCHEDULE
- 10/30/25 - Form 10-Q
- CTNM's page on the SEC website